Baxter (BAX) – Company Press Releases
-
Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.
-
Baxter to Host First-Quarter 2024 Financial Results Conference Call for Investors
-
Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health
-
Baxter Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy
-
Baxter to Host Annual Meeting of Stockholders in Virtual Format
-
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference
-
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
-
Baxter to Present at Raymond James 45th Annual Institutional Investors Conference
-
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
-
Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™
-
Spectral Medical Announces Amendment and Extension of Exclusive Supply and Distribution Agreement With Baxter Healthcare Corporation
-
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference
-
Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients
-
Baxter Declares Quarterly Dividend
-
Baxter Reports Fourth-Quarter and Full-Year 2023 Results
-
New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload
-
Baxter to Host Fourth-Quarter 2023 Financial Results Conference Call for Investors
-
Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter
-
Baxter Advances First Intravenous (IV) Bag Recycling Pilot for U.S. Hospitals
-
Baxter to Present at 42nd Annual J.P. Morgan Healthcare Conference
-
Baxter Publishes Task Force on Climate-Related Financial Disclosures (TCFD) Report and Is Named to Dow Jones Sustainability Index North America
-
Spectral Medical Provides November Tigris Trial Update
-
The Baxter International Foundation and UNICEF Partner to Expand Access to Safe Water and Sanitation in Egypt
-
New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients
-
Baxter Declares Quarterly Dividend
-
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Nuwellis, Inc. Announces Third Quarter 2023 Financial Results
-
Spectral Medical Provides Tigris Trial Update
-
Baxter Highlights New Data at Kidney Week Indicating Sharesource Is Associated With a 77% Lower Risk of Home Dialysis Technique Failure
-
Baxter Reports Third-Quarter 2023 Results
-
Nuwellis Announces Board of Directors Transition
-
Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device
-
Nuwellis, Inc. To Announce Third Quarter 2023 Financial Results on November 7, 2023
-
Nuwellis Announces Closing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
-
Baxter Launches Digital Image Capture Capability for PanOptic Plus Ophthalmoscope
-
Nuwellis Announces Pricing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
-
Nuwellis Provides Regulatory Update on SeaStar Medical’s Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption
-
Baxter Appoints Joel Grade Chief Financial Officer
-
Advent International and Warburg Pincus Complete Acquisition of Baxter’s BioPharma Solutions Business
-
Baxter to Host Third-Quarter 2023 Financial Results Conference Call for Investors
-
Nuwellis to Present at the Gilmartin Group Emerging Growth Showcase
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Baxter, Rain, and Danaher, and Encourages Investors to Contact the Firm
-
BAXTER INTERNATIONAL, INC. (NYSE: BAX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Baxter Inte
-
ROSEN, A LEADING LAW FIRM, Encourages Baxter International Inc. Investors With Losses to Secure Counsel Before Important September 11 Deadline in Securities Class Action – BAX
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Seagate, Baxter, and Rain and Encourages Investors to Contact the Firm
-
Baxter to Present at Morgan Stanley 21st Annual Global Healthcare Conference
-
BAXTER INTERNATIONAL, INC. (NYSE: BAX) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Baxter I
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Baxter International Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BAX
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioXcel, Seagate, and Baxter and Encourages Investors to Contact the Firm
Back to BAX Stock Lookup
